Whales with a lot of money to spend have taken a noticeably bearish stance on Pacira BioSciences.
Looking at options history for Pacira BioSciences PCRX we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $1,074,286 and 2, calls, for a total amount of $100,285.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $27.5 for Pacira BioSciences, spanning the last three months.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Pacira BioSciences options trades today is 3259.17 with a total volume of 1,370.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Pacira BioSciences's big money trades within a strike price range of $20.0 to $27.5 over the last 30 days.
Pacira BioSciences Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PCRX | PUT | TRADE | BEARISH | 08/16/24 | $6.0 | $5.3 | $5.95 | $25.00 | $731.8K | 5.6K | 4 |
| PCRX | PUT | SWEEP | BEARISH | 08/16/24 | $6.3 | $5.8 | $5.8 | $25.00 | $116.7K | 5.6K | 1.2K |
| PCRX | PUT | SWEEP | BEARISH | 11/15/24 | $3.6 | $3.2 | $3.4 | $20.00 | $76.0K | 5.0K | 50 |
| PCRX | PUT | SWEEP | BEARISH | 08/16/24 | $2.8 | $2.0 | $2.8 | $20.00 | $68.6K | 5.4K | 76 |
| PCRX | CALL | SWEEP | BULLISH | 08/16/24 | $1.65 | $1.65 | $1.65 | $25.00 | $54.2K | 3.0K | 6 |
About Pacira BioSciences
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Present Market Standing of Pacira BioSciences
- With a trading volume of 755,168, the price of PCRX is down by -1.61%, reaching $20.72.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 23 days from now.
What The Experts Say On Pacira BioSciences
In the last month, 4 experts released ratings on this stock with an average target price of $41.75.
- An analyst from Piper Sandler persists with their Overweight rating on Pacira BioSciences, maintaining a target price of $42.
- Reflecting concerns, an analyst from Barclays lowers its rating to Equal-Weight with a new price target of $25.
- An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $57.
- An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $43.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pacira BioSciences with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
